Newsfeeds - Spark Newswire

3 minute read

Cellectis Reported Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab (FCA) with no Dose-Limiting Toxicities in BALLI-01 Phase 1 Study at ASH 2021; Said Preliminary Data Demon…

Today, 2:56 AM

Cellectis (Nasdaq: CLLS), a clinical-stage biotechnology company employing its pioneering TALEN® gene-editing platform to develop innovative therapeutics for the treatment of serious diseases, announced today preliminary results from the BALLI-01 Phase 1 study of UCART22, its allogeneic CAR-T cell therapy candidate target

CLLS

1 minute read

JMP Securities Initiates Coverage On Cellectis with Market Outperform Rating, Announces Price Target of $20

By Benzinga Newsdesk

Today, 2:56 AM

JMP Securities analyst Silvan Tuerkcan initiates coverage on Cellectis (NASDAQ:CLLS) with a Market Outperform rating and announces Price Target of $20.

CLLS

1 minute read

Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China

By Vandana Singh

Today, 2:56 AM

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ:CLLS) have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells. The expanded agreement will…

CLLS

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Monday, Nov. 15, 2021: Z, LMT, GOOG, NET, U, CLLS, CDXS, TAK, VEEV, REGN, INTU, OPEN

By Benzinga Newsdesk

Today, 2:56 AM

Zillow Group (Z) Lockheed Martin (LMT) Alphabet (GOOG) Cloudflare (NET) Unity Software (U) Cellectis (CLLS) Codexis (CDXS) Takeda Pharmaceutical Co (TAK) Veeva Systems (VEEV) Regeneron Pharmaceuticals

CDXS

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Monday, Nov. 8, 2021: PRLB, COIN, U, CSTL, CLLS

By Benzinga Newsdesk

Today, 2:56 AM

Proto Labs (PRLB) Coinbase Global (COIN) Unity Software (U) Castle Biosciences (CSTL) Cellectis (CLLS)

CLLS

1 minute read

Cellectis Announces Release Of Abstracts At ASH Showcasing Updated Preliminary Clinical Data From BALLI-01 Study And First Preclinical Data From TALGlobin01

By Benzinga Newsdesk

Today, 2:56 AM

Cellectis S.A. (NASDAQ:CLLS, EURONEXT GROWTH: ALCLS)) (the “Company”), a gene-editing company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene

CLLS

32 minute read

Earnings Scheduled For November 4, 2021

By Benzinga Insights

Today, 2:56 AM

Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.

AAOI